These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 2407894)

  • 1. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
    Atzpodien J; Kirchner H
    Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An explanation of the variable clinical response to interleukin 2 and LAK cells.
    Parmiani G
    Immunol Today; 1990 Apr; 11(4):113-5. PubMed ID: 2187466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
    Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
    J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interleukin 2: immunologic background and clinical use in tumor therapy].
    Dummer R; Welters H; Keilholz U; Tilgen W; Burg G
    Hautarzt; 1990 Feb; 41(2):53-5. PubMed ID: 2180854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies.
    Sosman JA; Hank JA; Sondel PM
    Semin Oncol; 1990 Feb; 17(1 Suppl 1):22-30; discussion 38-41. PubMed ID: 2405492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.
    Boccoli G; Masciulli R; Ruggeri EM; Carlini P; Giannella G; Montesoro E; Mastroberardino G; Isacchi G; Testa U; Calabresi F
    Cancer Res; 1990 Sep; 50(18):5795-800. PubMed ID: 2118421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive therapies: quo vadis?
    Clark JW; Longo DL
    Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy for cancer.
    Rosenberg SA
    Sci Am; 1990 May; 262(5):62-9. PubMed ID: 2333496
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adoptive immunotherapy in malignant tumors].
    Kiselevskiĭ MV
    Vestn Ross Akad Med Nauk; 2003; (1):40-4. PubMed ID: 12608084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 therapy for human cancer.
    van Hoesel QG
    Lung; 1990; 168 Suppl():1069-74. PubMed ID: 2117107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
    Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M
    Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
    Rosenberg SA; Lotze MT; Yang JC; Aebersold PM; Linehan WM; Seipp CA; White DE
    Ann Surg; 1989 Oct; 210(4):474-84; discussion 484-5. PubMed ID: 2679456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
    Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
    J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.